Abstract. The timing and synchronization of postnatal myelination in the human central nervous system (CNS) are complex. We found eight time-related patterns of CNS myelination during the first two postnatal years in autopsied infants. The intensity of myelination was graded in 162 infants with diverse diseases on an ordinal scale ofdegrees 0-4. The Ayer method for maximum likelihood estimates for censored data was utilized to generate curves of the temporal changes in the percent of infants with degrees 0 through 4 of myelin in 62 white matter sites. These sites fall into eight subgroups determined by the presence or absence of microscopic myelin (degree I) at birth and the median age at which mature myelin (degree 3) is reached. There is variability in the timing of myelination within and across axonal systems, and early onset of myelination is not always followed by early myelin maturation. We reexamined general rules governing the timing of myelination proposed by previous investigators, and found that those rules are neither complete nor inviolate, and that there is a complex interplay among them. This study specifies distinct periods of maturation in which myelinating pathways are potentially vulnerable to insult during the first two postnatal years.
INTRODUCTION
Human central nervous system (CNS) myelination begins in the fetal period and continues into adulthood, with dramatic changes in the first two postnatal years. Several investigators have made important observations over the last century about anatomic relationships within the sequences of myelination and have proposed general rules about the control of this dynamic process (1-7). After the fetal period, however, studies of human myelination have been limited by poorly defined quantitative methods for comparing the degrees of myelination among brains at different ages, as well as by the use of small numbers of cases separated by lengthy time intervals. The use of a large sample size is important to characterize inherent variation among individuals, particularly in an infant autopsy population in whom variable or unknown effects of disease or treatment upon myelination are unavoidable factors (8).
